\n<\/p>\n
From elder care and telemedicine to neutraceuticals and more, Novo offers a broad range of solutions<\/em><\/p>\n Imagine being able to diversify your holdings in the health-care market with just one stock. Actually, you don\u2019t have to imagine it because this goal is achievable right now with Novo Integrated Sciences, Inc. (NVOS).<\/p>\n Not only that, but you\u2019ll get immediate exposure to top-of-the-line medical-care technology with a position in NVOS stock, at a highly affordable price point.<\/p>\n Ultimately, Novo Integrated Sciences is pioneering a holistic approach to patient-first health and wellness. The company is meeting and exceeding this objective through a multidisciplinary health-care ecosystem of services and product innovation.<\/p>\n This is the type of asset which you can just buy and hold for years, as the health-care industry is bound to grow over time and Novo\u2019s multifaceted business model is designed to grow along with the market.<\/p>\n A Closer Look at NVOS Stock<\/strong><\/p>\n I\u2019m glad that you\u2019re reading this article today, as you\u2019ve found the perfect entry point for a long-term position in NVOS stock.<\/p>\n Just in the past month, the stock has spiked above $1.50 multiple times. NVOS stock has also bounced off of $1.30 many times, so it appears that there are buyers ready to swoop in when the stock gets to that price point.<\/p>\n The stock happens to be $1.30 as I\u2019m writing this, so hopefully you\u2019ll already have a self-directed broker and be ready to make a move.<\/p>\n And by the way, NVOS stock has reached $2 and higher, so the possibility of a 2x move or even more is entirely possible.<\/p>\n An Essential Patent<\/strong><\/p>\n Among the most important components of Novo\u2019s business is the company\u2019s patented NHP 2.0 platform and proprietary production process.<\/p>\n For instance, the NHP 2.0 platform enables the company to implement its Advanced Nutraceutical Manufacturing segment with unique, proprietary manufacturing capabilities. Through this platform, Novo is able to preserve product efficacy from batch to batch and bring nutraceuticals into line with the rigors of pharmaceutical grade manufacturing.<\/p>\n Here\u2019s how it works. With NHP 2.0, Novo develops specialty ingredients and formulations, creates a biological signature of ingredients, and examines drug-to-drug interactions, thereby lowering the risk and cost of clinical trials. In other words, Novo can take the ingredients, research and define them, and optimize the composition to provide an improved formula and an end product with reproducible efficacy.<\/p>\n As you can see, Novo is truly committed to advancing breakthrough science. The company even has a subsidiary, known as acenzia, that\u2019s dedicated to providing personalized diagnostics and identifying innovative therapeutics specific to particular ailments.<\/p>\n What really sets acenzia apart from its competitors is its robust science platform. To that end, the company has dedicated a large percentage of it 36,000 square foot lab to world-class R&D laboratories with unique capabilities to handle complex chemical combinations and biologics.<\/p>\n A Game Changer in Telehealth<\/strong><\/p>\n Telemedicine, also known as telehealth, is a rapidly growing market in the wake of Covid-19.<\/p>\n On April 1, 2020, the Novo Family launched the Novo Telemedicine Platform, through which a number of multidisciplinary primary health care clinicians have been providing low-cost virtual contact with elder-care clients for physiotherapy sessions, non-critical resident reviews, and exercise-related activity.<\/p>\n Novo is fully prepared to continue the company\u2019s efforts to develop and expand the Novo Telemedicine Platform.<\/p>\n